Safety & Feasibility Study of the Chartis System With Heterogeneous

Clinical Trial Description

n/a

Study Design

Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic

See also
Status	Clinical Trial	Phase
Recruiting	`NCT01902732` - Endoscopic Lung Volume Reduction After Catheter-based CV Measurement in Patients With Heterogeneous Emphysema and Complete Interlobar Fissures	Phase 2/Phase 3
Completed	`NCT02022683` - To Improve Lung Function and Symptoms for Emphysema Patients Using Zephyr Valves	N/A
Completed	`NCT00825578` - Use of Endobronchial Valves in Non-Upper Lobe Heterogeneous Emphysema	Phase 3

See also

Status

Clinical Trial

Phase

Recruiting

NCT01902732 - Endoscopic Lung Volume Reduction After Catheter-based CV Measurement in Patients With Heterogeneous Emphysema and Complete Interlobar Fissures

Phase 2/Phase 3

Completed

NCT02022683 - To Improve Lung Function and Symptoms for Emphysema Patients Using Zephyr Valves

N/A

Completed

NCT00825578 - Use of Endobronchial Valves in Non-Upper Lobe Heterogeneous Emphysema

Phase 3

Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.

Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.

Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

NCT number	NCT00684892
Study type	Interventional
Source	Pulmonx, Inc.
Contact
Status	Completed
Phase	Phase 1/Phase 2
Start date	May 2008
Completion date	November 2008

Safety and Feasibility Study of the Chartis System With Heterogeneous Emphysema Prior to Endobronchial Lung Volume Reduction (ELVR)

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms